Peptide news, regulation & research, verified daily.
PeptideKnow tracks FDA and HHS actions, clinical trial readouts and the science behind 128 research peptides, with every claim linked to its primary source.
- Peptide profiles
- 128
- News reports
- 68
- Dosage protocols
- 121
- Categories
- 21
The briefing
Latest peptide news

Regulation & Policy
Medicare Starts Paying for Obesity Drugs Today — Bridge Program Opens $50 Access for Millions
Medicare's new $50 Bridge program covering Wegovy, Zepbound, Foundayo, and oral Wegovy for obesity launched July 1 — the first Medicare weight-loss benefit.
Regulation & Policy
FDA staff urges caution on compounded peptides ahead of July advisory meeting
Regulation & Policy
FDA Accepts Sandoz's Two ANDAs for Generic Tirzepatide — First Generic Path for Mounjaro and Zepbound
Regulation & Policy
FDA Import Alert 66-80 Puts GLP-1 Peptide APIs on DWPE Detention Track
Industry & Market
Lexaria Begins Dosing GLP-1-H26-7: Oral DehydraTECH-Semaglutide Goes Head-to-Head With Wegovy Tablets
Research & Discovery
Wisconsin Group Shows Class B1 GPCR Peptides Can Drop the Helix — and Pick Their Pathway
Regulatory tracker
Where the most-searched peptides stand
FDA approval, compounding and trial status, updated as rules change. Not medical or legal advice.
Explore by function
Browse peptide categories
Most read profiles
Popular peptides
BPC-157
BPC-157 is a synthetic 15-amino acid peptide derived from a naturally occurring protective protein isolated from human gastric juice.
Research dose200-500 mcg/day Weight Loss & MetabolicClinical trialsRetatrutide
Retatrutide is an investigational first-in-class triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously.
Research dose1-12 mg/week (Phase II range) Healing & RecoveryCompounding under HHS policyTB-500
TB-500 is a synthetic heptapeptide corresponding to the N-acetylated active fragment (amino acids 17–23) of the endogenous 43-amino acid signaling …
Research dose2-5 mg/week Weight Loss & MetabolicFDA-approvedSemaglutide
Semaglutide is an FDA-approved synthetic 31-amino acid analog of glucagon-like peptide-1 (GLP-1), modified with a C18 fatty acid chain via a linker…
Research dose0.25-2.4 mg/week (subcutaneous); 3-14 mg/day (oral) Skin & HairPCAC review pendingGHK-Cu
GHK-Cu is a naturally occurring tripeptide copper complex (glycyl-L-histidyl-L-lysine) first identified in human plasma in the 1970s.
Research dose1-2 mg/day injectable; topical concentrations 0.1-2% Weight Loss & MetabolicFDA-approvedTirzepatide
Tirzepatide is an FDA-approved first-in-class dual GIP/GLP-1 receptor agonist peptide that simultaneously activates both glucose-dependent insulino…
Research dose2.5-15 mg/week MitochondrialCompounding under HHS policyMOTS-c
MOTS-c is a 16-amino acid mitochondrial-derived peptide (MDP) encoded by a short open reading frame within the 12S rRNA gene of mitochondrial DNA.
Research dose5-10 mg/week Growth Hormone SecretagoguesFDA Category 2Ipamorelin
Ipamorelin is a selective synthetic pentapeptide growth hormone secretagogue, developed as part of a major chemistry program targeting GHRP analogs.
Research dose200-300 mcg/dose, 1-3x/dayFree tool
Reconstitution calculator
Enter vial size and bacteriostatic water volume to get concentration and exact syringe units, with preset ranges for 128 peptides.
Open the calculatorGuides
Beginner's guide to peptidesWhat peptides are, how they work, legal status and safety basics. Peptide stacking guideCommon combinations and the evidence behind each. How to reconstitute peptidesStep by step, with storage and troubleshooting. Routes of administrationSubcutaneous, oral, nasal and topical compared. Peptides vs SARMsMechanisms, safety and legal status side by side.Questions
Frequently asked questions
What is PeptideKnow?
An independent reference and news site covering 128 research peptides, with mechanisms of action, dosage protocols from published research, stacking guides, clinical data and daily regulatory news, including FDA compounding rules under sections 503A and 503B.
Are research peptides FDA-approved?
Most are not. BPC-157, TB-500 and MOTS-c are not FDA-approved drugs. A few peptides, such as semaglutide, tirzepatide, tesamorelin and bremelanotide (PT-141), are approved for specific indications. Each profile shows its current status.
Where does PeptideKnow get its data?
From primary sources: FDA and HHS announcements and dockets, the Federal Register, ClinicalTrials.gov, PubMed-indexed research and company disclosures. Every news report links to the documents it relies on.
How often is PeptideKnow updated?
The news section is updated every day. Peptide profiles are revised whenever regulatory status or trial data changes.

